133 related articles for article (PubMed ID: 26104856)
1. Wogonoside induces growth inhibition and cell cycle arrest via promoting the expression and binding activity of GATA-1 in chronic myelogenous leukemia cells.
Li H; Hui H; Xu J; Yang H; Zhang X; Liu X; Zhou Y; Li Z; Guo Q; Lu N
Arch Toxicol; 2016 Jun; 90(6):1507-22. PubMed ID: 26104856
[TBL] [Abstract][Full Text] [Related]
2. Wogonin induces cell cycle arrest and erythroid differentiation in imatinib-resistant K562 cells and primary CML cells.
Yang H; Hui H; Wang Q; Li H; Zhao K; Zhou Y; Zhu Y; Wang X; You Q; Guo Q; Lu N
Oncotarget; 2014 Sep; 5(18):8188-201. PubMed ID: 25149543
[TBL] [Abstract][Full Text] [Related]
3. Wogonoside exerts growth-suppressive effects against T acute lymphoblastic leukemia through the STAT3 pathway.
Xiao R; Gan M; Jiang T
Hum Exp Toxicol; 2017 Nov; 36(11):1169-1176. PubMed ID: 27941168
[TBL] [Abstract][Full Text] [Related]
4. [Growth inhibition and differentiation of imatinib-resistant chronic myeloid leukemia cell induced by cell differentiation agent in vitro].
Wang XD; Qiu L; Lu RZ; Chen LJ; Zhan ZM; Han BH; Zhang BL; Ma J
Zhonghua Yi Xue Za Zhi; 2007 Dec; 87(48):3399-405. PubMed ID: 18476538
[TBL] [Abstract][Full Text] [Related]
5. Bone marrow microenvironment confers imatinib resistance to chronic myelogenous leukemia and oroxylin A reverses the resistance by suppressing Stat3 pathway.
Li X; Miao H; Zhang Y; Li W; Li Z; Zhou Y; Zhao L; Guo Q
Arch Toxicol; 2015 Jan; 89(1):121-36. PubMed ID: 24671465
[TBL] [Abstract][Full Text] [Related]
6. Wogonoside induces cell cycle arrest and differentiation by affecting expression and subcellular localization of PLSCR1 in AML cells.
Chen Y; Hui H; Yang H; Zhao K; Qin Y; Gu C; Wang X; Lu N; Guo Q
Blood; 2013 May; 121(18):3682-91. PubMed ID: 23487022
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of the dual PI3K and mTOR inhibitor NVP-BEZ235 in combination with imatinib mesylate against chronic myelogenous leukemia cell lines.
Xin P; Li C; Zheng Y; Peng Q; Xiao H; Huang Y; Zhu X
Drug Des Devel Ther; 2017; 11():1115-1126. PubMed ID: 28435223
[TBL] [Abstract][Full Text] [Related]
8. Homoharringtonine suppresses imatinib resistance via the Bcl-6/p53 pathway in chronic myeloid leukemia cell lines.
Wang Q; Ding W; Ding Y; Ma J; Qian Z; Shao J; Li Y
Oncotarget; 2017 Jun; 8(23):37594-37604. PubMed ID: 28410239
[TBL] [Abstract][Full Text] [Related]
9. A molecular and biophysical comparison of macromolecular changes in imatinib-sensitive and imatinib-resistant K562 cells exposed to ponatinib.
Yandim MK; Ceylan C; Elmas E; Baran Y
Tumour Biol; 2016 Feb; 37(2):2365-78. PubMed ID: 26373734
[TBL] [Abstract][Full Text] [Related]
10. Pharmacologic targeting of the P-TEFb complex as a therapeutic strategy for chronic myeloid leukemia.
Qing Y; Wang X; Wang H; Hu P; Li H; Yu X; Zhu M; Wang Z; Zhu Y; Xu J; Guo Q; Hui H
Cell Commun Signal; 2021 Aug; 19(1):83. PubMed ID: 34372855
[TBL] [Abstract][Full Text] [Related]
11. LW-213, a newly synthesized flavonoid, induces G2/M phase arrest and apoptosis in chronic myeloid leukemia.
Liu X; Hu P; Li H; Yu XX; Wang XY; Qing YJ; Wang ZY; Wang HZ; Zhu MY; Guo QL; Hui H
Acta Pharmacol Sin; 2020 Feb; 41(2):249-259. PubMed ID: 31316178
[TBL] [Abstract][Full Text] [Related]
12. In Vitro Antileukemia Activity of ZSTK474 on K562 and Multidrug Resistant K562/A02 Cells.
Zhou Q; Chen Y; Chen X; Zhao W; Zhong Y; Wang R; Jin M; Qiu Y; Kong D
Int J Biol Sci; 2016; 12(6):631-8. PubMed ID: 27194941
[TBL] [Abstract][Full Text] [Related]
13. Wogonoside induces apoptosis in human non-small cell lung cancer A549 cells by promoting mitochondria dysfunction.
Luo M; Mo J; Yu Q; Zhou S; Ning R; Zhang Y; Su C; Wang H; Cui J
Biomed Pharmacother; 2018 Oct; 106():593-598. PubMed ID: 29990847
[TBL] [Abstract][Full Text] [Related]
14. BCR-ABL/GATA1/miR-138 mini circuitry contributes to the leukemogenesis of chronic myeloid leukemia.
Xu C; Fu H; Gao L; Wang L; Wang W; Li J; Li Y; Dou L; Gao X; Luo X; Jing Y; Chim CS; Zheng X; Yu L
Oncogene; 2014 Jan; 33(1):44-54. PubMed ID: 23208504
[TBL] [Abstract][Full Text] [Related]
15. Use of deferasirox, an iron chelator, to overcome imatinib resistance of chronic myeloid leukemia cells.
Kim DS; Na YJ; Kang MH; Yoon SY; Choi CW
Korean J Intern Med; 2016 Mar; 31(2):357-66. PubMed ID: 26874514
[TBL] [Abstract][Full Text] [Related]
16. A Systems Pharmacology Approach Uncovers Wogonoside as an Angiogenesis Inhibitor of Triple-Negative Breast Cancer by Targeting Hedgehog Signaling.
Huang Y; Fang J; Lu W; Wang Z; Wang Q; Hou Y; Jiang X; Reizes O; Lathia J; Nussinov R; Eng C; Cheng F
Cell Chem Biol; 2019 Aug; 26(8):1143-1158.e6. PubMed ID: 31178408
[TBL] [Abstract][Full Text] [Related]
17. Sonic hedgehog signaling regulates Bcr-Abl expression in human chronic myeloid leukemia cells.
Liao HF; Su YC; Zheng ZY; Jhih Cai C; Hou MH; Chao KS; Chen YJ
Biomed Pharmacother; 2012 Jul; 66(5):378-83. PubMed ID: 22397755
[TBL] [Abstract][Full Text] [Related]
18. A novel tubulin polymerization inhibitor, MPT0B206, downregulates Bcr-Abl expression and induces apoptosis in imatinib-sensitive and imatinib-resistant CML cells.
Chen CW; Lee YL; Liou JP; Liu YH; Liu CW; Chen TY; Huang HM
Apoptosis; 2016 Sep; 21(9):1008-18. PubMed ID: 27344662
[TBL] [Abstract][Full Text] [Related]
19. MiRNA-409-5p dysregulation promotes imatinib resistance and disease progression in children with chronic myeloid leukemia.
Liu YY; Jiao WY; Li T; Bao YY
Eur Rev Med Pharmacol Sci; 2019 Oct; 23(19):8468-8475. PubMed ID: 31646577
[TBL] [Abstract][Full Text] [Related]
20. BM microenvironmental protection of CML cells from imatinib through Stat5/NF-κB signaling and reversal by Wogonin.
Xu X; Zhang X; Liu Y; Yang L; Huang S; Lu L; Wang S; Guo Q; Zhao L
Oncotarget; 2016 Apr; 7(17):24436-54. PubMed ID: 27027438
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
